Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy of the extended release formulation of tacrolimus
(Advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately with
cyclosporine A because of side effects and/or non-responsiveness.